Category Archives: Uncategorized

The manuscript “Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy” has been published. Int J Mol Sci. 2023 Nov 29;24(23):16901. doi: 10.3390/ijms242316901.

The article ” Phase 1 study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed an/or refractory multiple myeloma” has been published. Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7.

https://www.redhillbio.com/news/news-details/2021/RedHill-Biopharma-Reports-Further-Analysis-of-Phase-23-Data-Including-a-62-Reduction-in-Mortality-with-Oral-Opaganib-in-Moderately-Severe-COVID-19-Patients/default.aspx

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=19347The

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=19319

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16275

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16270

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16265

https://www.globenewswire.com/news-release/2020/05/08/2030275/0/en/RedHill-Biopharma-Receives-FDA-Approval-for-COVID-19-Clinical-Study-with-Opaganib-in-the-U-S.html

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=13253